REPARE THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.5 USD | -3.85% |
|
+1.45% | -52.05% |
| May. 08 | Top Premarket Gainers | MT |
| May. 08 | Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 59.87M | Sales 2025 * | 11.16M | Capitalization | 149M |
|---|---|---|---|---|---|
| Net income 2024 * | -101M | Net income 2025 * | -168M | EV / Sales 2024 * | -1.58 x |
| Net cash position 2024 * | 243M | Net cash position 2025 * | 249M | EV / Sales 2025 * | -9.03 x |
| P/E ratio 2024 * |
-1.54
x | P/E ratio 2025 * |
-1.07
x | Employees | 179 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.95% |
More Fundamentals
* Assessed data
More news
Latest transcript on Repare Therapeutics Inc.
More recommendations
More press releases
More news
| 1 day | -3.85% | ||
| 1 week | +1.45% | ||
| Current month | +12.90% | ||
| 1 month | -11.17% | ||
| 3 months | -54.72% | ||
| 6 months | -8.85% | ||
| Current year | -52.05% |
1 week
3.26
3.96
1 month
2.983.98
Current year
2.988.49
1 year
2.9813.85
3 years
2.9835.75
5 years
2.9846.44
10 years
2.9846.44
| Managers | Title | Age | Since |
|---|---|---|---|
Lloyd Segal
CEO | Chief Executive Officer | 60 | 16-05-31 |
Steve Forte
DFI | Director of Finance/CFO | 45 | 19-09-30 |
Michael Zinda
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | 19-02-28 |
Lloyd Segal
CEO | Chief Executive Officer | 60 | 16-05-31 |
Ann Rhoads
BRD | Director/Board Member | 58 | 20-06-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.33% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 3.5 | -3.85% | 289,644 |
| 24-05-09 | 3.64 | -3.96% | 724,885 |
| 24-05-08 | 3.79 | +15.55% | 4,588,930 |
| 24-05-07 | 3.28 | -3.53% | 73,158 |
| 24-05-06 | 3.4 | -1.45% | 118,440 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Companyâs initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
Calendar
2024-06-17
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.5
USD
Average target price
15.33
USD
Spread / Average Target
+338.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -52.05% | 149M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- RPTX Stock
